Who is sponsoring NCT00743431?

NCT00743431 is sponsored by Merck Sharp & Dohme LLC.

What condition does NCT00743431 study?

NCT00743431 studies Ovarian Neoplasms.

What drugs are being tested in NCT00743431?

Interventions: Caelyx (Pegylated Lyposomal Doxorubicin).

What is the status of NCT00743431?

NCT00743431 is currently COMPLETED.

Last reviewed 2015-03-26 · How we verify

Caelyx in Ovarian Cancer: Prevention and Treatment of Infusion Reactions and Palmar-plantar Erythrodysesthesia (PPE).

NCT00743431 COMPLETED Results posted

The purpose of this study is to evaluate the safety and tolerability of Caelyx in women with advanced ovarian cancer, focusing on infusion reactions and palmar-plantar erythrodysesthesia.

Details

Lead sponsor	Merck Sharp & Dohme LLC
Status	COMPLETED
Enrolment	224
Start date	2005-02
Completion	2008-12

Conditions

Ovarian Neoplasms

Interventions

Caelyx (Pegylated Lyposomal Doxorubicin)

Primary outcomes

Occurrences of Infusion Reactions and Palmar-Plantar Erythrodysesthesia (PPE) — The observational program was conducted over a period of 2 years
Definitions in assessment of adverse event severity: Mild: awareness of sign, symptom, or event, but easily tolerated. Moderate: discomfort enough to cause interference with usual activity and may warrant intervention. Severe: incapacitating with inability to do usual activities or significantly affects clinical status, and warrants intervention.